🔔 Penalty Alert
Dr Reddys Laboratories' subsidiary penalized Rs 28.7 lakh by Kazakhstan Revenue Authority for disallowance of certain expense claims for CY 2021.
Dr Reddys Laboratories Ltd Analyst Rating
based on 39 analysts
28.21%
Buy
35.90%
Hold
35.90%
Sell
Based on 39 analysts offering long term price targets for Dr Reddys Laboratories Ltd. An average target of ₹1336.87
Source: S&P Global Market Intelligence
Dr Reddys Laboratories Ltd Share analysis
Dr Reddys Laboratories Ltd price forecast by 39 analysts
Upside of7.83%
High
₹1655
Target
₹1336.87
Low
₹969
Dr Reddys Laboratories Ltd target price ₹1336.87, a slight upside of 7.83% compared to current price of ₹1253.7. According to 39 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddys Laboratories Ltd revenue growth forecast
Expected growth rate Q1, FY2026:23.73%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddys Laboratories Ltd EPS growth forecast
EPS estimate Q1, FY2026:7.01%
Forecast
Actual
Source: S&P Global Market Intelligence
Dr Reddys Laboratories Ltd Performance
Day's Low
Day's High
₹1,236.35₹1,255.1552 Week's Low
52 Week's High
₹1,074₹1,421.49
| Returns % | |
| 1 Month Return | -4.78 % |
| 3 Month Return | -7.02 % |
| 1 Year Return | + 8.18 % |
| Market Stats | |
| Previous Close | ₹1,239.85 |
| Open | ₹1,246.00 |
| Volume | 17.17L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,03,451.19Cr |
Dr Reddys Laboratories Ltd Key Statistics
| P/E Ratio | 19.34 |
| PEG Ratio | 6.77 |
| Market Cap | ₹1,03,451.19 Cr |
| P/B Ratio | 4.22 |
| EPS | 66.882 |
| Dividend Yield | 0.65 |
| Sector | Pharmaceuticals |
| ROE | 19.42 |
Dr Reddys Laboratories Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,03,451.19 Cr | 22.89% | 0.52 | ₹5,577 Cr | ₹28,011 Cr | |
| HOLD | ₹1,61,834.96 Cr | 48.35% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,13,763.33 Cr | 52.62% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹45,052.52 Cr | 5.97% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹30,218.76 Cr | 0.16% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Dr Reddys Laboratories Ltd Mutual Fund Holdings
About Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Share Price: ₹1253.70 per share as on 06 Dec, 2024 04:01 PM
Market Capitalisation: ₹1,03,451.19Cr as of today
Revenue: ₹8,016.10Cr as on September 2024 (Q3 24)
Net Profit: ₹1,341.90Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddys Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Dr Reddys Laboratories Ltd
Dr. Reddy's Subsidiary Fined by Kazakhstan Authorities - 06 Dec, 2024
Dr. Reddy's Laboratories announced that its subsidiary in Kazakhstan has been fined Rs 28.7 lakh due to a local tax dispute regarding expense claims for 2021.Dr Reddy's Unit Fined ₹28.7 Lakh in Kazakhstan - 05 Dec, 2024
Dr Reddys Laboratories announced that its subsidiary in Kazakhstan has been fined ₹28.7 lakh for disallowed expense claims. The company stated that this penalty will not materially impact its financials or operations.Dr Reddy's Focuses on Innovation and Market Growth - 04 Dec, 2024
Dr Reddy's Laboratories aims to enhance its domestic market position through innovation and new product launches, while also expanding its consumer health segment.Dr. Reddy’s Launches First NPC Immuno-Oncology Drug - 30 Nov, 2024
Dr. Reddy’s Laboratories has launched Toripalimab in India, the first immuno-oncology drug for nasopharyngeal carcinoma. This positions India as the third country to access this treatment, which shows a 48% reduction in disease progression risk when combined with standard chemotherapy.Dr Reddys Launches Cancer Drug, Stock Rises - 29 Nov, 2024
Dr Reddys Laboratories launched Toripalimab, an immunooncology drug for nasopharyngeal carcinoma, marking a significant milestone. The stock rose 2.1% following the announcement.Dr. Reddy's Launches First Immuno-Oncology Drug in India - 28 Nov, 2024
On November 28, Dr. Reddy's Laboratories launched Toripalimab, India's first immuno-oncology drug for nasopharyngeal carcinoma, after securing exclusive rights through a licensing agreement. This launch addresses a significant unmet medical need and positions India as the third country to access this treatment.Dr. Reddy's Faces Competition from Biocon - 26 Nov, 2024
Dr. Reddy's Laboratories competes with Biocon in the global pharmaceutical market, particularly in generics and biosimilars. While Dr. Reddy's has a strong presence in the US, Biocon's lower valuation and aggressive expansion into emerging markets make it a formidable competitor.Dr Reddys Laboratories Issues Product Recall in US - 25 Nov, 2024
Dr Reddys Laboratories is recalling 3,416 bottles of IBU (ibuprofen) 600 mg tablets in the US due to manufacturing issues, initiated on October 29. The recall is classified as Class III, indicating low risk of adverse health consequences.Dr Reddys Partners with Telangana for New Facilities - 22 Nov, 2024
Dr Reddys Laboratories, along with five leading pharmaceutical companies, has signed memorandums of understanding with the Telangana government to establish manufacturing facilities in Pharma City.Dr Reddy's Faces Regulatory Setback, Shares Decline - 21 Nov, 2024
Dr Reddy's Laboratories shares dropped 3.2% following the USFDA's issuance of a Form 483 with seven observations from a recent inspection of its Hyderabad facility. The company reported a decline in net profit for Q2 FY25 but noted revenue growth.USFDA Inspection at Dr Reddy's API Facility - 20 Nov, 2024
The USFDA conducted a GMP inspection at Dr Reddy's API manufacturing facility in Bollaram, Hyderabad, issuing a Form 483 with seven observations.Dr. Reddy's Receives USFDA Observations at Hyderabad Plant - 19 Nov, 2024
Dr. Reddy's Laboratories announced it received seven observations from the USFDA following a GMP inspection at its Hyderabad API facility. The company is committed to addressing these observations promptly.Dr. Reddy's Faces Recall and Market Decline - 18 Nov, 2024
Dr. Reddy's Laboratories faced a recall of Morphine Sulfate tablets due to manufacturing issues, leading to a 2.14% drop in shares. Additionally, Zydus announced a co-marketing agreement for a biosimilar with Dr. Reddy's, providing potential future revenue.Dr Reddys Laboratories Issues Recall for Morphine Tablets - 17 Nov, 2024
Dr Reddys Laboratories is recalling Morphine Sulfate extended-release tablets in the US due to manufacturing issues, including failed impurities and degradation specifications. The recall affects 2,040 bottles of 15 mg and 532 bottles of 30 mg strengths.Dr Reddy's Penalized by Mexican Drug Regulator - 14 Nov, 2024
Dr Reddys Laboratories has been fined Rs 27 lakh by Mexico's drug regulator for deviations in import filing guidelines, including invoice date errors and reference standard discrepancies.Dr Reddy's Laboratories Positioned for Growth - 13 Nov, 2024
Dr Reddy's Laboratories, a leading Indian pharma company, is well-positioned for growth due to its strong R&D focus, diverse product portfolio, and favorable currency dynamics. The company is expected to benefit from a weaker rupee and supportive US drug pricing policies, enhancing its export potential. Financial projections indicate steady revenue and profit growth through FY24.Dr Reddy's Aims for Top Five in Indian Pharma Market - 11 Nov, 2024
Dr Reddy's Laboratories plans to rise to the fifth position in the Indian pharma market within five years, focusing on brand planning, collaborations, innovation, and inorganic growth. The company aims for double-digit growth, leveraging its recent acquisition of Sanofi India's vaccine portfolio and exploring M&A opportunities in chronic therapies.Dr. Reddy's Participates in Green Pharma City Review - 08 Nov, 2024
Madan Mohan Reddy and representatives from major pharma companies attended a review meeting on the Green Pharma City project in Hyderabad, led by Telangana's IT and Industries Minister.Dr. Reddy's Releases Results and Target Price Update - 07 Nov, 2024
Dr. Reddy's Laboratories released its unaudited financial results for Q2 and H1 FY2024, maintaining FY26E estimates with a target price of INR 1,329 and an upgraded rating to HOLD.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 3 quarters, 7.31K Cr → 8.35K Cr (in ₹), with an average increase of 6.4% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 10.05% to 10.86% in Sep 2024 quarter
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 26.65% to 26.64% in Sep 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.39K Cr → 1.25K Cr (in ₹), with an average decrease of 9.8% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 10.19% to 9.97% in Sep 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 27.68% to 27.53% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, DRREDDY stock has moved down by -4.8%
Dr Reddys Laboratories Ltd Financials
Index Inclusions
Dr Reddys Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | ||
| Foreign Institutions | 27.53% | ||
| Mutual Funds | 10.86% | 8.06 | |
| Retail Investors | 9.97% | ||
| Others | 24.99% |
Dr Reddys Laboratories Ltd Key Indicators
Dr Reddys Laboratories Ltd Valuation
Dr Reddys Laboratories Ltd in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (19.34x)
December 5, 2024
Industry (57.40x)
December 5, 2024
Highest (53.88x)
December 18, 2020
Dr Reddys Laboratories Ltd Earnings and Dividends
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit fell -15.28% since last year same period to ₹1,255.70Cr in the Q2 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated -9.82% fall in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 6.38%.
Read More about Dividends
Dr Reddys Laboratories Ltd Technicals Summary
Bearish
Neutral
Bullish
Dr Reddys Laboratories Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Dr Reddys Laboratories Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Dr Reddys Laboratories Ltd shares.
Dr Reddys Laboratories Ltd (DRREDDY) share price today is ₹1253.7
Dr Reddys Laboratories Ltd is listed on NSE
Dr Reddys Laboratories Ltd is listed on BSE
- Today’s highest price of Dr Reddys Laboratories Ltd is ₹1255.15.
- Today’s lowest price of Dr Reddys Laboratories Ltd is ₹1236.35.
PE Ratio of Dr Reddys Laboratories Ltd is 19.34
PE ratio = Dr Reddys Laboratories Ltd Market price per share / Dr Reddys Laboratories Ltd Earnings per share
Today’s traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 17.17L.
Today’s market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹103451.19Cr.
| Dr Reddys Laboratories Ltd(DRREDDY | Price |
|---|---|
52 Week High | ₹1421.49 |
52 Week Low | ₹1074 |
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹1253.7. It is down -11.80% from its 52 Week High price of ₹1421.49
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹1253.7. It is up 16.73% from its 52 Week Low price of ₹1074
| Dr Reddys Laboratories Ltd(DRREDDY | Returns |
|---|---|
1 Day Returns | 13.85% |
1 Month Returns | -4.78% |
3 Month Returns | -7.02% |
1 Year Returns | 8.18% |